These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28423678)

  • 1. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
    Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
    Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
    Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
    Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
    Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
    Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
    Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
    Pistillo MP; Carosio R; Grillo F; Fontana V; Mastracci L; Morabito A; Banelli B; Tanda E; Cecchi F; Dozin B; Gualco M; Salvi S; Spagnolo F; Poggi A; Queirolo P
    Clin Immunol; 2020 Jun; 215():108428. PubMed ID: 32344017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
    Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS
    Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
    Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
    Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
    Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
    J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
    Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL
    Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
    Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
    Soldevilla MM; Villanueva H; Meraviglia-Crivelli D; Menon AP; Ruiz M; Cebollero J; Villalba M; Moreno B; Lozano T; Llopiz D; Pejenaute Á; Sarobe P; Pastor F
    Mol Ther; 2019 Nov; 27(11):1878-1891. PubMed ID: 31405808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.